Drug Discovery Chemistry is a dynamic conference for medicinal, biophysical, and computational chemists working across pharma, biotech, and academia. Focused on discovery and optimization challenges of small-molecule and macrocyclic drug candidates, the 2026 event features new sessions spanning AI- and ML-driven design, fragment- and structure-based discovery, molecular glues and degraders, DNA-encoded libraries, and emerging biophysical tools. Attendees can tailor their experience by exploring concurrent tracks covering today’s most innovative approaches to drug discovery.
Speakers from industry are strongly represented each year. In 2025, participating organizations included AbbVie, AstraZeneca, Bayer, Bristol Myers Squibb, Genentech, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda, and numerous emerging biotechs. Preliminary agendas have recently been announced—reserve your place by December 12 to take advantage of special early savings.